German giant Boehringer Ingelheim has announced the licensing of antibody drug conjugate (ADC) technology from Synaffix B.V., a subsidiary of Switzerland’s Lonza (SWX: LONN). This strategic deal is expected to significantly enhance Boehringer’s ADC portfolio, driven by its subsidiary, NBE Therapeutics.
Agreement Details
Under the terms of the agreement, Synaffix will provide access to its proprietary ADC technologies for an agreed but undisclosed number of targets. The first target was nominated upon signing, with additional targets to be nominated within a predefined timeframe. In addition to an upfront payment, Synaffix is eligible to receive potential additional milestone payments of up to USD 1.3 billion, plus additional royalty payments on net sales of resulting products.
Synaffix’s Technology and Expertise
Synaffix, a biotech company focused on the development of best-in-class ADCs, boasts a clinically validated ADC platform technology. This technology utilizes enzymatic modification of natural glycosyl anchor sites on antibodies to develop best-in-class ADCs or bispecific antibodies (BsAbs). The partnership with Boehringer Ingelheim will leverage Synaffix’s innovative platform to advance the development of novel therapies.
Significance of the Partnership
This partnership between Boehringer Ingelheim and Synaffix underscores the commitment of both companies to advancing innovative treatments in the field of oncology. By combining Synaffix’s cutting-edge ADC technology with Boehringer’s development and commercialization capabilities, the collaboration aims to bring new and effective therapies to patients in need.-Fineline Info & Tech
